Advancing a class on top of statins
Investors & Media

2016 Press Releases

Webcast ImageGemphire Announces Future Development Plans of Gemcabene for Hypercholesterolemic Patients (Replay)09/19/17 at 4:30 p.m. ET

Gemphire Announces Future Development Plans of Gemcabene for Hypercholesterolemic Patients
Tuesday, September 19, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageGemphire Therapeutics, Inc. at Cantor Fitzgerald Global Healthcare Conference (Live)09/26/17 at 8:00 a.m. ET

Gemphire Therapeutics, Inc. at Cantor Fitzgerald Global Healthcare Conference
Tuesday, September 26, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016
DateTitle  
11/29/16Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
LIVONIA, Mich., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on November 25, 2016, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Gemphire’s Inducement Plan, as a material inducement to one individual entering into employment with Gemphire.  The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public ann... 
Download PDFPrinter Friendly Version
11/28/16Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
ROYAL-1 is a Phase 2b Study to Determine Safety and Tolerability of Gemcabene in Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy Topline Data Readout Anticipated in Second Half 2017 LIVONIA, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition t... 
Download PDFPrinter Friendly Version
11/17/16Gemphire Therapeutics to Present at the Piper Jaffray Healthcare and LD Micro Main Event Conferences
LIVONIA, Mich., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that Mina Sooch, President and Chief Executive Officer, will present corporate updates at the Piper Jaffray 28th Annual Healthcare Conference and the LD Micro Main Event conference. Gemphire’s product candidate, gemcabene, is a novel, once-daily... 
Download PDFPrinter Friendly Version
11/02/16Gemphire Announces Third Quarter 2016 Financial Results and Provides Corporate Update
LIVONIA, Mich., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced its financial results for the third quarter and nine months ended September 30, 2016 and provided a corporate update. "Since the successful closing of our initial public offering in August, we continued to make excellent progress in the devel... 
Download PDFPrinter Friendly Version
10/31/16Gemphire Therapeutics Strengthens Intellectual Property with Granting of European Patent for Gemcabene
Global Patents for Gemcabene Provide Coverage Past 2030 with Focus on Severe Hypertriglyceridemia Patients at Risk of Pancreatitis LIVONIA, Mich., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, today announced that the European Patent Office has granted European Patent No. 2658536 Gemcabene and Derivatives for Treating Pancreatitis cove... 
Download PDFPrinter Friendly Version
10/26/16Gemphire Therapeutics to Report Third Quarter Financial Results and Corporate Update on November 2; Corporate Presentation at the 25th Annual Credit Suisse Healthcare Conference on November 7
LIVONIA, Mich., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that it will issue a press release announcing financial results for the third quarter ended September 30, 2016 on Wednesday, November 2.  The Company also announced that Mina Sooch, Gemphire’s CEO, will... 
Download PDFPrinter Friendly Version
10/17/16Gemphire Therapeutics Proudly Sponsors the FH Foundation
LIVONIA, Mich., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, is once again a proud sponsor of the FH Global Summit being held in Dallas, TX this year and the Advocates for Awareness program, an educational campaign by the FH Foundation that focuses on community outreach and strives to raise awareness of this vastly under diagnosed and ... 
Download PDFPrinter Friendly Version
10/07/16Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LIVONIA, Mich., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, today announced that on October 3, 2016, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved three equity awards und... 
Download PDFPrinter Friendly Version
10/06/16Gemphire Therapeutics Appoints Lee Golden, M.D., as Chief Medical Officer
Interventional Cardiologist with Extensive Biotech and Large Cap Pharma Experience; Brings Expertise in Research & Development, Clinical Operations and Regulatory Affairs NORTHVILLE, Mich., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, and N... 
Download PDFPrinter Friendly Version
09/26/16Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia
Phase 2b Study to Determine Safety and Tolerability of Gemcabene in HoFH Topline Data Readout Currently Anticipated in First Half -2017 LIVONIA, Mich., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty live... 
Download PDFPrinter Friendly Version
09/22/16Gemphire Therapeutics to Present Corporate Overview at the Ladenburg Thalmann 2016 Healthcare Conference
LIVONIA, Mich., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that Mina Sooch, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalm... 
Download PDFPrinter Friendly Version
09/19/16Gemphire Therapeutics Announces Publication of Phase 2 Data for Gemcabene in the Journal of Clinical Lipidology
Gemcabene as Add-On to Stable Statin Therapy in Hypercholesterolemic Patients Demonstrated Additional Dose Dependent and Statistically Significant Reductions in LDL-C and CRP Compared to Placebo LIVONIA, Mich., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiov... 
Download PDFPrinter Friendly Version
08/10/16Gemphire Therapeutics Announces Closing of Initial Public Offering
NORTHVILLE, Mich., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease) today announced the closing of its previously announced initial public offering of 3,000,000 shares of its common stock at a pr... 
Download PDFPrinter Friendly Version
08/04/16Gemphire Therapeutics Announces Pricing of Initial Public Offering
NORTHVILLE, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease) today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per sha... 
Download PDFPrinter Friendly Version